Therapex steps up to the challenge to develop innovative therapeutics by leveraging excellent scientific experience

Therapex is dedicated to creating new standards of care for cancer patients with the potential to be the best or first in class

Therapex builds a diversified pipeline with assets that inhibit key oncogenic drivers or boost the immune system

Therapex promises to reach the apex of therapeutics based on our expertise of developing novel medicines.
The Apex of
Therapeutics
PIPELINE
Immuno-Oncology
Developing small molecule-based anti-cancer drugs for treating the solid tumors resistant to the existing therapeutic agents
Targeted Oncology
Developing precision medicines that targets mutated-EGFR in non-small cell lung cancer (NSCLC) patients
PROTAC
Developing the targeted protein degraders that converts the undruggable to the druggable
R&D
Creative thinking and innovative technology
Therapex endeavors to provide better solutions for the patients with incurable diseases
view more
Merit
Competitive new drug
development technology
Experts in
Drug Discovery
Specialty in drug R&D and broad web
over human network
In-silico
Modeling
Agility in lead generations with expertise on
molecular modeling and design
In-house
Infra
Proficiency in medical chemistry and pharmacological
assessment that expedite the research progress
Therapeutic
New Modality
Know-how on developing PROTACs that directly degrade
and eradicate the disease-related bio-molecules
Media release
view more
NEWS
2022.06.28

IBCC to rename as "Therapex" and call for professional perso..

박지연 이사, 김우식 임재홍 박사 등 스카우트인터파크바이오컨버전스(Interpark Bio Convergence)는 4일 임시..
NEWS
2022.06.28

IBCC to team up with Elsen Therapeutics for development of TPD-based a..

TPD 항암제 발굴 위한 상호협력.."2024년 전임상 개발 시작 목표"▲태현섭 엘젠 대표(왼쪽), 이구 ..
NEWS
2022.06.28

IBCC to focus on pharmaceutical R&D, moving on from e-commerce industr

이구 인터파크바이오컨버전스 대표서울대 화학교육과 학사·카이스트 화학과 석사·아이오와대 화학과 박사·프린스턴대 화학과 포닥/ ..
NEWS
2022.06.28

IBCC to move to a new R&D nest with expansion of professional manpower

신약발굴 위한 의약화학 실험실 문정동 연구소에 마련..고형암 면역항암제 'IBC-1131' 내년초 IND신청 목표인터파크 자..
NEWS
2022.06.28

Dr. Koo Lee, vice president of IBCC, to serve as a CEO

이구 인터파크바이오 부사장, 대표직 맡는다기존홍준호 사장, IPO 앞둔 지아이이노베이션 부사장으로 합류인터파크바이오컨버전스..
NEWS
2022.06.28

IBCC to contract with Bisichem for an anti-cancer drug candidate with ..

인터파크바이오컨버전스, 비씨켐에 항암제 후보물질 기술도입료 총 100억원 지급인터파크가 올해 7월 설립한 자회사 인터파크바이오..